{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Papaverine Concentrations for Vasospasm Prevention in Radial Artery Grafts"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "RA segments were harvested from 10 CABG patients."
      },
      "Participants": {
        "score": 2,
        "evidence": "RA segments were harvested from 10 CABG patients."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The segments were randomly assigned to two groups: 0.5 mg/ml papaverine (n=12) and 2 mg/ml papaverine (n=12)."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the efficacy of two papaverine concentrations (0.5 mg/ml and 2 mg/ml) for preventing vasospasm and their impact on endothelial integrity in radial artery (RA) grafts used in coronary artery bypass graft (CABG) surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the vasodilatory effect, assessed using ex vivo myography over 60 minutes."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was achieved using a computer-generated sequence, and allocation was concealed."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not applicable."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "The segments were randomly assigned to two groups: 0.5 mg/ml papaverine (n=12) and 2 mg/ml papaverine (n=12)."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The 2 mg/ml papaverine group demonstrated stronger vasodilatation (mean difference = 24.67%, 95% CI 15.23 to 34.11; p < 0.001) but caused more endothelial damage (mean difference = 22.63%, 95% CI 8.91 to 36.35; p = 0.002) compared to the 0.5 mg/ml group."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not reported."
      }
    },
    "total_score": 16,
    "max_score": 25
  },
  "model": "gpt-4o"
}